Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

New

BioSim™ anti-Evolocumab (Human) ELISA Kit

A Sandwich ELISA kit for the Qualitative measurement of antibodies to Evolocumab in serum or plasma samples

WARNING: This product can expose you to chemicals including TMB, which is known to the State of California to cause cancer, For more information go to www.P65Warnings.ca.gov.
Catalog #: E5027
$1,290.00

Product Details

Cat # +Size E5027-100
Size 96 assays
Detection Method Absorbance (450 nm)
Species Reactivity Human
Applications Sandwich ELISA kit used for in vitro Qualitative determination of antibodies to Evolocumab in human serum and plasma samples
Features & Benefits ● Assay Precision: Intra-Assay and Inter-Assay CV < 30%
● Cross Reactivity: Except for Evolocumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins
● For in vitro Qualitative determination of antibodies to Evolocumab in human serum and plasma samples
Kit Components ● Microtiter Plate
● Positive Control
● Negative Control
● Assay Buffer
● HRP-conjugate Probe
● TMB substrate (Avoid light)
● Stop Solution
● Wash buffer (20X)
● Plate sealers
Storage Conditions 4ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Evolocumab is a human IgG2 monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a serine protease that binds to LDL receptors on the hepatocyte cell surface and promotes the lysosome-mediated degradation of these receptors. This results in decreased uptake and clearance of LDL-C (bad cholesterol) by the receptors. The monoclonal antibody binds to PCSK9 and prevents interaction with the LDL receptor. This promotes the recycling of the internalized LDL receptor to the hepatocyte cell surface and increased removal of LDL-C from the blood. The original drug received approval from the FDA to treat homozygous and heterozygous familial cholesterolemia. The drug has also been approved to treat patients with high cholesterol, whose LDL-C was not controlled by the statin treatment. However, upon administration of the antibody, patients tend to develop an immune response that results in the formation of anti-Evolocumab antibodies, thus adversely affecting the therapeutic response to treatment. BioSim™ anti-Evolocumab ELISA kit qualitatively measures antibodies to Evolocumab in human serum or plasma samples. The kit is based on the Sandwich ELISA principle. Standards and samples (serum or plasma) are added to the microtiter plate coated with Evolocumab. After incubation, the wells are washed. The HRP conjugated probe is added and binds to the antibodies to Evolocumab that is captured by Evolocumab coated on the wells. Following incubation, wells are washed and the enzymatic activity is detected by the addition of TMB chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies to Evolocumab in the sample or standard. The qualitative test results can be evaluated using cut-off values.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.